Cambiotics has successfully closed a Seed investment round of EUR ~4 million with an international consortium, led by the investor Collaborative Fund, with participation from EIFO (Danish Export and Investment Fund), and True, as co-investors.
The pioneering biotech company, founded with support from Cambridge Enterprise and the BioInnovation Institute, is developing next-generation health solutions, built on findings from the Patil Lab that certain species of gut bacteria can take in and store per- and polyfluoroalkyl substances (PFAS), supporting their natural excretion from the body.
The funding will enable Cambiotics to advance its scientific and clinical roadmap in 2026, including the initiation of its first human clinical trial in the United States and preparations for the US launch of its debut product, 46&, later this year.
Peter Holme Jensen, CEO of Cambiotics, expressed his enthusiasm for the funding’s potential: “The partnership with Collaborative Fund, EIFO, and True that this funding represents, also marks the next phase of Cambiotics development, where focus will be on upscaling of products, clinical validation, and first launch of product in the US market.”
Professor Kiran Patil said: “This timely investment will enable Cambiotics to test its innovative probiotic in a clinical setting. We are excited to see our basic science discovery getting a step closer to removing PFAS 'forever chemicals' from the human body.”
Read more on the Cambiotics and MRC Toxicology Unit websites.